Drug storage microneedle and its preparation method and application
Through simplified preparation technology and biocompatible materials, the existing microneedle structure and cumbersome process of microneedles in the storage of medicine are solved, and flexible drug management and low-cost production of microneedles in the storage of medicine are realized, which improves the long-term release efficiency of treatment and Patient comfort.
Patent Information
- Application Number
- CN202311222034.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-21
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-09-21
AI Technical Summary
The existing microneedle storage drug storage has complex structure, cumbersome process, long preparation time, high cost, and the biocompatibility of the materials needs to be verified, making it difficult to transform clinically.
Using silicon wafers as patches, setting up the drug storage cavity and multiple microneedles, and preparing drug storage microneedles by prefabricating, impregnating, curing and patch setting of polydimethylsiloxane templates, using hyaluronic acid and collagen. , sodium alginate and other biocompatible materials form drug storage cavity and microneedle, simplifying the process flow and reducing costs.
It realizes flexible adjustment of drug storage, real-time drug addition and control, reduces skin damage, improves long-term drug release efficiency and patient comfort for treatment, simplifies the preparation process and reduces costs.
Smart Images

Figure CN118079217B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical device technology, relates to the field of microneedle technology, and specifically relates to a drug storage microneedle and a preparation method and application thereof. Background Art
[0002] The concept of microneedles was first proposed in 1976. However, due to the limitations of micromachining technology, it was not experimentally introduced as an alternative tool for transdermal drug delivery until the late 1990s. Unlike traditional methods, the minimally invasive method of microneedles has a crucial advantage over traditional methods. It is a form of injection. The diameter of the needle is about one-tenth of a hair, and the pain of inserting it into the skin is much less than that of an ordinary needle. Microneedle transdermal drug delivery has a wide range of applications, such as in the field of daily beauty, loading effective cosmetic ingredients, promoting transdermal penetration, and thus achieving better skin care effects; in the field of plastic surgery, loading hyaluronic acid and other cosmetic filling materials to achieve cosmetic effects; in the field of skin diseases, loading effective therapeutic drugs for scars, promoting transdermal transport, and enhancing treatment effects; in the field of imaging, loading contrast agents, improving transdermal methods, and achieving minimally invasive and painless imaging.
[0003] The microneedles actually used are divided into solid microneedles, hollow microneedles, coated microneedles, hydrogel microneedles, and dissolving microneedles. However, no matter which form of microneedles is used to deliver drugs, they do not have the function of storing drugs. In response to this problem, many useful explorations have been made in the prior art, such as the Chinese invention patent with patent number CN113648530A, which discloses a press-type double-drug storage layer microneedle patch, and the Chinese invention patent with patent number CN105963855A, which discloses a microneedle drug delivery patch containing a separate drug storage capsule.
[0004] The push-type double-drug reservoir microneedle patch includes an adhesive layer, a microneedle array module mounted on the adhesive layer, and a drug-carrying layer module fixedly connected to the microneedle array module. The adhesive layer includes a sticky inner surface and a non-sticky outer surface, the microneedle array module is smaller than the adhesive layer and is mounted on the inner surface of the adhesive layer; the microneedle array module includes a substrate and a microneedle array. The microneedle drug delivery patch containing a detachable drug storage capsule includes a detachable and replaceable drug storage capsule, a drug-carrying end integrating a microneedle array and a microfluidic channel network, a drug delivery end integrating a microneedle array and a microfluidic channel network, and an adhesive patch that can attach the microneedle drug delivery patch to the skin. The drug storage capsule is detachable and can be replaced according to the needs of drug delivery.
[0005] It can be seen from this that the drug-storing microneedles of the existing technology have complex structures, cumbersome processes, long preparation times, high costs, and the biocompatibility of the materials used needs to be verified, making clinical transformation difficult. Summary of the invention
[0006] The present invention is directed to the above-mentioned problems. The first purpose is to provide a drug-storing microneedle; the second purpose is to provide a method for preparing the drug-storing microneedle; and the third purpose is to provide an application of the drug-storing microneedle as a transdermal drug delivery device.
[0007] In order to achieve the above object, the specific technical solution adopted by the present invention is as follows:
[0008] In a first aspect of the present invention, a drug storage microneedle is provided, comprising a patch, a drug storage cavity arranged on the patch, a spacer layer arranged on the bottom surface of the drug storage cavity, and a plurality of microneedles arranged on the spacer layer, wherein the drug storage cavity space corresponds to all the microneedles.
[0009] Preferably, the patch is a silicon wafer of 0.1 to 0.3 mm; the base diameter of the microneedles is 200 to 500 μm, the height is 500 to 1200 μm, and the needle tip spacing is 500 to 1200 μm.
[0010] Preferably, the substrate material of the microneedle is selected from one or more of hyaluronic acid, collagen, sodium alginate, and chitosan; the drug loaded on the microneedle includes one or more of pheniramine, sodium aescinate, nintedanib, and amethoxazole.
[0011] The second aspect of the present invention provides a method for preparing the above-mentioned drug storage microneedle, comprising the following steps:
[0012] A. Template prefabrication
[0013] Polydimethylsiloxane (PDMS) is used as the template material, and micro molds with different pinhole arrangements and aperture sizes are pre-made according to actual needs.
[0014] In the present invention, the PDMS template can flexibly adjust the number of arrays, the distance between needle tips, the base diameter and height of the needle cavity, the volume of the drug reservoir, etc. through design. For example, the base diameter of each needle cavity is 200-700 μm, the height is 500-1200 μm, the pinholes can be arranged in arrays of 10×10, 12×12, 15×15, and 20×20, and the distance between needle tips is 500-1200 μm.
[0015] B. Dipping
[0016] The base material pre-gel is evenly mixed on the PDMS micro mold, and the air bubbles are removed by negative pressure and then centrifuged to force the base material pre-gel into the needle hole; this process will be repeated several times to ensure that the needle tip is completely filled with the gel solution.
[0017] Among them, the base material can be selected from hyaluronic acid, collagen, sodium alginate, chitosan and other materials, and a single material or a mixture of multiple materials can be used as the base material;
[0018] The conditions for negative pressure removal of bubbles are vacuuming at 0.08-0.1 MPa for 2-3 min; the centrifugal conditions are 3000-4000 rpm for 5-6 min, which can be adjusted according to the specific substrate material used.
[0019] C. Curing
[0020] Depending on the properties of the substrate material, the microneedles are directly dried and cured or heat concentrated and then light cured. The specific curing method is selected and adjusted according to the substrate material used.
[0021] D. Preparation of drug storage cavity
[0022] Continue to add the base material pre-gel to the micro mold, and place a PDMS block above the microneedle part as the drug storage cavity area, solidify after multiple negative pressure debubbling and centrifugation, and then take out the PDMS block to form a drug storage cavity. The material of the drug storage cavity can be the same as or different from the microneedle base material.
[0023] E. Patch settings
[0024] After the micro-mold in step E is cured, the microneedle is removed from the mold, and then a patch is attached to the back of the microneedle using a medical waterproof adhesive resin (such as waterproof epoxy resin). After drying overnight, the drug is injected into the drug storage cavity.
[0025] The preparation process of the drug storage microneedle in the present invention is basically as shown above. When different substrate materials are selected, the specific process conditions of different steps are adjusted to a certain extent, as shown below:
[0026] (1) When the substrate material of the microneedle is selected from hyaluronic acid, the mass concentration of hyaluronic acid is 20-50wt%. First, the pre-gel solution of oligomeric hyaluronic acid (20-50wt%) is uniformly mixed on the PDMS micro mold, and then vacuumed (0.08-0.1MPa, 2-3min) with negative pressure to remove bubbles, and centrifuged at 3000-4000rpm for 5-6min to force the mixture into the needle hole. This process will be repeated several times to ensure that the needle tip is completely filled with the gel solution. Subsequently, the microneedle is placed in a desiccator at room temperature overnight.
[0027] After drying, continue to add the base material pre-gel to the micro mold, and place a PDMS block above the microneedle part as the drug storage cavity area. After multiple negative pressure debubbling and centrifugation, take out the PDMS block to form a drug storage cavity. After complete drying, remove the microneedle from the mold, and then use a medical waterproof adhesive resin (such as waterproof epoxy resin) to attach the patch to the back of the microneedle. After drying overnight, inject the drug into the drug storage cavity.
[0028] (2) When the substrate material of the microneedle is selected from collagen, the mass volume concentration of the collagen hydrogel GelMA is 10%; during the dipping process, the micro mold is heated in a 50° C. water bath under negative pressure to remove bubbles, and this is repeated three times to ensure that the needle tip is completely filled with the gel solution;
[0029] The curing method in the microneedle preparation process is as follows: the defoamed micro mold is placed in an oven at 35°C for 6 hours to be heated and concentrated until it becomes viscous, avoiding over-drying; then a hydrogel precursor solution with a mass volume concentration of 20% is added dropwise again, and placed in an oven at 35°C for 5 hours; after taking it out, it is photocured with 405nm UV light;
[0030] When preparing the drug storage cavity, first add a PVA solution with a mass volume concentration of 20%, and place a PDMS block to form a drug storage cavity, put it in an oven at 35°C to dry overnight, and remove the microneedle from the mold after it is completely dried.
[0031] The third aspect of the present invention provides the use of the above-mentioned drug storage microneedle in the preparation of a transdermal drug delivery device. The drug storage microneedle of the present invention can be used to treat diseases such as lymphedema, scars, periodontitis, and dandruff. After the corresponding drug is injected into the drug storage cavity, the microneedle is pushed into the diseased tissue with the help of a needle pusher, and the drug in the drug storage cavity is slowly released into the diseased tissue.
[0032] The experimental results of the rabbit ear thickened scar model showed that the microneedles prepared by the present invention can effectively achieve minimally invasive treatment of scars. After 30 days of treatment, the appearance of the scars was significantly improved and basically restored to normal skin condition, which was close to the results of the direct drug treatment group, but the pain of microneedle treatment was significantly reduced.
[0033] A fourth aspect of the present invention provides a transdermal drug delivery device, characterized in that it includes a drug-storing microneedle and a needle-pushing device for inserting the microneedle into a tissue, wherein the drug-storing microneedle is as described above.
[0034] Functions and Effects of the Invention
[0035] (1) In terms of structure, the present invention provides an integrated structure of a microneedle and a drug storage cavity. The drug storage capacity can be adjusted according to the size of the prepared drug storage cavity, and a maximum drug storage capacity of 2 mL can be achieved. Excessive drug loading may cause the microneedle to have an excessive weight, thereby achieving flexible adjustment of the drug storage capacity.
[0036] (2) In terms of treatment, the integrated structure of the microneedle and drug storage cavity of the present invention can add drugs in real time and control the amount of drugs added. Existing microneedles without drug storage cavities generally directly mix the drug and the solution for preparing the microneedles during preparation, which will cause uneven distribution of drug molecules when forming microneedles. Drugs with large molecular weights will be deposited on the microneedle needle tip, and a large amount of drug molecules will be released while piercing the skin, which cannot be used for long-term treatment. Drugs with small molecular weights will be deposited on the microneedle base, and the amount of drug delivered into the skin is very small, resulting in a large amount of drug loss, and multiple treatments are required. The microneedles prepared by the present invention can meet both long-term local drug release and sufficient drug delivery. There is no need to pierce the skin with microneedles multiple times, and the damage to the skin is minimal.
[0037] (3) In terms of treatment operation, the microneedle of the present invention has strong penetration force and is easy to operate, which can be completed by the patient by himself; the microneedle is less invasive, which reduces the pain of the patient; the microneedle is used for drug transport and is equipped with a closed drug storage cavity to avoid secondary contamination.
[0038] (4) The present invention uses hyaluronic acid as the base material to prepare a microneedle and drug storage cavity integrated structure, and for the first time completes the administration of pirfenidone in the form of a microneedle dosage form.
[0039] (5) The base material of the microneedle of the present invention can be selected from one or more of hyaluronic acid, collagen, sodium alginate, and chitosan. After the microneedle head enters the skin, it can gradually dissolve by itself and gradually release the drug in the microneedle.
[0040] (6) In terms of preparation, the present invention forms a microneedle substrate by adding a pregel solution to a polydimethylsiloxane (PDMS) template, then adding an appropriate amount of pregel solution, embedding a PDMS block to form a drug storage space, and finally sealing a layer of silicon wafer with a waterproof epoxy resin to prepare a microneedle with a drug storage cavity. The microneedle substrate and the drug storage cavity can be prepared using different materials according to different requirements, and can be a single material or two or more materials.
[0041] Compared with the existing preparation process of integrated drug storage microneedles, it has the characteristics of simple preparation, simple process, low cost, and simplifies the process flow. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The figure is a flow chart of the preparation of the drug storage microneedle of the present invention;
[0043] Figure 2 is a microscopic structure diagram of the drug storage microneedle of the present invention;
[0044] Figure 3 This is a picture of the dissolution of the microneedle tip after the drug storage microneedle of the present invention penetrates into the skin;
[0045] Figure 4 This is the experimental result of the rabbit ear thickening scar model of the present invention;
[0046] Figure 5 These are the Masson's trichrome staining results of scar tissue in different groups. DETAILED DESCRIPTION
[0047] The present invention is described in detail below in conjunction with the embodiments and the accompanying drawings. However, the following embodiments should not be considered as limiting the scope of the present invention.
[0048] The reagents and raw materials used in the present invention are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight.
[0049] Figure 1 The preparation flow chart of the drug storage microneedle of the present invention is shown, and the general steps are as follows:
[0050] A. Template prefabrication
[0051] Polydimethylsiloxane (PDMS) is used as the template material, and micro molds with different pinhole arrangements and aperture sizes are pre-made according to actual needs.
[0052] In the present invention, the PDMS template can flexibly adjust the number of arrays, the distance between needle tips, the base diameter and height of the needle cavity, the volume of the drug reservoir, etc. through design. For example, the base diameter of each needle cavity is 200-700 μm, the height is 500-1200 μm, the pinholes can be arranged in arrays of 10×10, 12×12, 15×15, and 20×20, and the distance between needle tips is 500-1200 μm.
[0053] B. Dipping
[0054] The base material pre-gel is evenly mixed on the PDMS micro mold, and the air bubbles are removed by negative pressure and then centrifuged to force the base material pre-gel into the needle hole; this process will be repeated several times to ensure that the needle tip is completely filled with the gel solution.
[0055] Among them, the base material can be selected from hyaluronic acid, collagen, sodium alginate, chitosan and other materials, and a single material or a mixture of multiple materials can be used as the base material;
[0056] The conditions for negative pressure removal of bubbles are vacuuming at 0.08-0.1 MPa for 2-3 min; the centrifugal conditions are 3000-4000 rpm for 5-6 min, which can be adjusted according to the specific substrate material used.
[0057] C. Curing
[0058] Depending on the properties of the substrate material, the microneedles are directly dried and cured or heat concentrated and then light cured. The specific curing method is selected and adjusted according to the substrate material used.
[0059] D. Preparation of drug storage cavity
[0060] Continue to add the base material pre-gel to the micro mold, and place a PDMS block above the microneedle part as the drug storage cavity area, solidify after multiple negative pressure debubbling and centrifugation, and then take out the PDMS block to form a drug storage cavity. The material of the drug storage cavity can be the same as or different from the microneedle base material.
[0061] E. Patch settings
[0062] After the micro-mold in step E is cured, the microneedle is removed from the mold, and then a patch is attached to the back of the microneedle using a medical waterproof adhesive resin (such as waterproof epoxy resin). After drying overnight, the drug is injected into the drug storage cavity.
[0063] The microscopic picture of the drug storage microneedle prepared by the above method is shown in Figure 2 , which shows the structure of drug-storing microneedles at different angles, including a patch, a drug storage cavity arranged on the patch, a spacer layer arranged on the bottom surface of the drug storage cavity, and a plurality of microneedles arranged on the spacer layer, and the drug storage cavity space corresponds to all the microneedles.
[0064] Since the microneedle base material can be selected from hyaluronic acid, collagen, sodium alginate, chitosan and other materials, which are soluble in the body, the microneedle head can gradually dissolve after entering the skin and gradually release the drug in the microneedle. Figure 3 .
[0065] Example 1: Preparation of 15×15 hyaluronic acid microneedles loaded with pirfenidone
[0066] A polydimethylsiloxane (PDMS) template of predetermined size was prepared in advance, that is, the base diameter and height of each needle cavity were 320 and 600 μm, respectively, the pinholes were arranged in a 15×15 array, and the needle tip spacing was 800 μm.
[0067] First, 200 μL of oligomeric hyaluronic acid (20 wt%) pre-gel solution was dripped onto the PDMS micro mold, and then the bubbles were removed by vacuum (~0.08 MPa, 3 min) and centrifuged at 4000 rpm for 5 min to force the mixture into the pinhole. This process was repeated twice to ensure that the needle tip was completely filled with gel solution; the microneedle was then placed in a desiccator at room temperature overnight; after complete drying, 500 μL of oligomeric hyaluronic acid (50 wt%) was added, and a PDMS block was placed to form a drug storage cavity; after complete drying, the microneedle was carefully removed from the mold, and a 0.3 mm thick silicon wafer was attached to the back of the microneedle using waterproof epoxy resin; after drying overnight, the pirfenidone drug solution was injected into the reservoir using a syringe.
[0068] The microneedle and drug storage cavity integrated structure prepared in this embodiment is used for the first time to deliver the pirfenidone drug in the form of a microneedle dosage form.
[0069] Example 2: Preparation of 12×12 GelMA (methacrylated) microneedles loaded with sodium aescinate
[0070] A polydimethylsiloxane (PDMS) template of predetermined size was prepared in advance, that is, the base diameter and height of each needle cavity were 410 and 900 μm, respectively, the pinholes were arranged in a 12×12 array, and the needle tip spacing was 750 μm.
[0071] First, add 200 μL of GelMA-60 hydrogel precursor (10% (w / v)) to the mold, and then remove bubbles under negative pressure in a 50°C water bath. Repeat this process three times. Place the debubbled mold in an oven and heat and concentrate at 35°C for 6 hours. Heat and concentrate until it becomes viscous, and avoid over-drying. Add 200 μL of GelMA-60 hydrogel precursor (20% (w / v)) again, place it in an oven and heat and concentrate it at 35°C for 5 hours. After taking it out, use 405nm UV light for photocuring. Finally, add 400 μL of PVA solution (20% (w / v)), and place a PDMS block to form a drug storage cavity. Place it in an oven and dry it at 35°C overnight. After it is completely dried, remove the microneedle from the mold, and use waterproof epoxy resin to attach a 0.2mm thick silicon wafer to the back of the microneedle. After drying overnight, inject the sodium aescinate drug solution into the reservoir with a syringe.
[0072] Example 3: Effect verification experiment
[0073] (1) Establishment of animal model
[0074] To establish a rabbit ear hypertrophic scar model, New Zealand white rabbits were anesthetized by intravenous injection of sodium pentobarbital (30 mg / kg) through the ear margin, and sodium pentobarbital was supplemented as needed to maintain surgical anesthesia. After disinfection, four full-thickness circular wounds (10 mm in diameter) were made on the ventral side of the rabbit ear, with a wound spacing greater than 10 mm. Most of the perichondrium was then removed with a scalpel, leaving the ear cartilage. Thirty days after surgery, the wound healed completely, and hypertrophic scars were observed at the modeling site with tissue bulges.
[0075] (2) Experimental groups
[0076] Treatment groups: mainly divided into five groups, namely: normal group; untreated group; pirfenidone drug treatment group; hyaluronic acid microneedle treatment group doped with L-type chiral molecules; hyaluronic acid microneedle treatment group doped with D-type chiral molecules. The preparation method of hyaluronic acid microneedle is shown in Example 1.
[0077] The dosage of treatment in different experimental groups: the normal group did not receive any treatment and was only a negative control group; the untreated group was injected with 200 μL of sterile PBS solution through the ear edge every day; the pirfenidone drug treatment group was injected with 200 μL of pirfenidone drug solution through the ear edge and was set as the positive control group; the hyaluronic acid microneedle treatment group doped with L-type chiral molecules inserted microneedles into the scar tissue every day, and then injected 200 μL of pirfenidone drug solution into the drug storage cavity through a syringe; the hyaluronic acid microneedle treatment group doped with D-type chiral molecules inserted microneedles into the scar tissue every day, and then injected 200 μL of pirfenidone drug solution into the drug storage cavity through a syringe. Each group was treated for 30 days.
[0078] (3) Experimental results and analysis
[0079] After 30 days of treatment, the appearance of scars in the treatment groups was significantly improved, except for the untreated group, and the scars in the other treatment groups were basically restored to normal skin state. Histologically, the scar surface became flatter, the dermis became thinner, and there was no large amount of inflammatory cell infiltration. However, the scar area in the untreated group continued to rise, with obvious hyperplasia of the dermis and epidermis, accompanied by a large amount of inflammatory cell infiltration ( Figure 4 In addition, Masson's trichrome staining showed that the collagen fibers in the untreated group were excessively deposited and arranged in disorder, while in the treated group, the collagen density decreased significantly and the arrangement was regular. Sirius red staining also found a similar trend, that is, after treatment, the Sirius red positive area decreased significantly, and there was basically no significant difference between normal skin and the treated group ( Figure 5 ).
[0080] The above results show that microneedles can achieve scar treatment in a minimally invasive way. Although there is no significant difference in the therapeutic effect between the microneedle group and the pirfenidone drug treatment group, compared with direct administration of drugs with a syringe at the scar tissue site, the pain of microneedle treatment is much reduced and the acceptability is significantly improved.
[0081] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. The present invention may be subject to various changes and improvements without departing from the spirit and scope of the present invention. These changes and improvements fall within the scope of the present invention. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A drug storage microneedle, characterized in that: The invention comprises a patch, a drug storage cavity arranged on the patch, a spacer layer arranged on the bottom surface of the drug storage cavity, and a plurality of microneedles arranged on the spacer layer, wherein the drug storage cavity space corresponds to all the microneedles. Wherein, the substrate material of the microneedle is selected from hyaluronic acid or GelMA-60 hydrogel, The preparation method of the drug storage microneedle is selected from any one of the following methods: Method 1: First, a 20wt% oligomeric hyaluronic acid pregel solution is dripped onto the micro mold, and then a negative pressure of 0.08-0.1MPa is used to remove bubbles, and the mixture is centrifuged at 4000rpm for 5min to force the mixture into the needle hole. The negative pressure vacuuming and centrifugation process is repeated twice to ensure that the needle tip is completely filled with the gel solution, and then the microneedle is placed in a desiccator at room temperature overnight; after complete drying, 50wt% oligomeric hyaluronic acid is continued to be added, and a PDMS block is placed to form a drug storage cavity. After complete drying, the microneedle is carefully removed from the mold, and a silicon wafer with a thickness of 0.1-0.3mm is attached to the back of the microneedle using a waterproof epoxy resin; after drying overnight, the drug solution is injected into the reservoir with a syringe, Method 2: First, add 10% w / v GelMA-60 hydrogel precursor solution to the micro mold, and then remove bubbles under negative pressure in a 50°C water bath; place the debubbled mold in an oven and heat it at 35°C for 6 hours, heat and concentrate it to a viscous state, and avoid over-drying; add the same volume of 20% w / v GelMA-60 hydrogel precursor solution again, place it in an oven and heat it at 35°C for 5 hours, take it out and photo-cure it with 405nm UV light; finally, add 2 times the volume of 20% w / v PVA solution, and place a PDMS block to form a drug storage cavity; place it in an oven and dry it at 35°C overnight. After it is completely dried, remove the microneedle from the mold, and use waterproof epoxy resin to attach a silicon wafer with a thickness of 0.1 to 0.3 mm to the back of the microneedle; after drying overnight, use a syringe to inject the drug solution into the reservoir.
2. The drug storage microneedle according to claim 1, characterized in that: in, The base diameter of the microneedle is 200-500 μm, the height is 500-1200 μm, and the needle tip spacing is 500-1200 μm.
3. The drug storage microneedle according to claim 1 or 2, characterized in that: in, The drugs loaded on the microneedles include one or more of pheniramine, sodium aescinate, nintedanib, and amethoprine.
4. The drug storage microneedle according to claim 1 or 2, characterized in that: in, Polydimethylsiloxane is used as the template material, and micro molds with different pinhole arrangements and aperture sizes are pre-made according to actual needs.
5. The drug storage microneedle according to claim 4, characterized in that: in, The base diameter of each needle cavity on the micromold is 200-700 μm, the height is 500-1200 μm, the pinholes can be arranged in arrays of 10×10, 12×12, 15×15, and 20×20, and the distance between the needle tips is 500-1200 μm; The time for negative pressure to remove bubbles is 2 to 3 minutes.
6. Use of the drug storage microneedle according to claim 1 or 2 in the preparation of a transdermal drug delivery device.
7. A transdermal drug delivery device, characterized in that: It comprises a drug-storage microneedle and a needle-pushing device for inserting the microneedle into a tissue, wherein the drug-storage microneedle is the drug-storage microneedle according to any one of claims 1 to 5.
